APYX Stock Forecast & Price Target

Apyx Medical Corp is experiencing strong revenue growth, with Surgical Aesthetics revenue expected to reach $43.0 million to $45.0 million, reflecting a year-over-year increase of 14% at the midpoint, and an upward revision of full-year revenue guidance to $50.5 million to $52.5 million. The company's successful launch of the AYON Body Contouring System and an increase in single-use handpiece sales have contributed to a 12% rise in total quarterly revenue, amounting to $12.9 million. Additionally, Apyx is poised to capture further market potential due to the rising demand for surgical-quality skin tightening procedures linked to the adoption of GLP-1 weight-loss drugs, indicating robust future growth prospects.

Apyx Medical Corp. has faced a downward adjustment in its Original Equipment Manufacturing (OEM) sales forecast, anticipating revenues of approximately $7.5 million, a decrease from the previously projected $8.0 million, primarily due to reduced sales volumes to existing clients. The company's stock performance has been adversely affected by ongoing challenges stemming from a March 2022 FDA warning letter, alongside competitive pressures related to increased usage of GLP-1 medications, contributing to volatility in its Surgical Aesthetics segment which comprises over 80% of total revenue. Additionally, Apyx Medical's cash position has declined to $25.1 million as of the end of Q3 2025 from $29.3 million in Q2 2025, raising concerns over financial stability amidst regulatory and macroeconomic challenges.